A patient portrayal of an attractive woman over 50 years old relaxing in a pink jumpter. She has flowing grey hair and her eyes are closed showing she feels great to be so well and healthy, thanks to Androfeme1.

A New Era in

Women's Health

in New Zealand

Patient portrayal

What is AndroFeme®1?

AndroFeme®1, is the first and only effective testosterone therapy for women registered in New Zealand for the treatment of hypoactive sexual desire dysfunction (HSDD) in post menopausal women.⁴

What is HSDD?

1 in 3 women between 40-64 experience HSDD

Hypoactive sexual desire dysfunction (HSDD) is the most common form of sexual dysfunction in women, defined by persistent and distressing low sexual desire. It can impact emotional well-being, relationships, and overall quality of life.¹⁻³

Find out more

1 in 3 Women between 40-64 will experience HSDD

Why choose AndroFeme®1?

Specifically formulated for women

Administered via a user-friendly applicator

Testosterone to help restore levels to those typical before menopause.⁴

III

Clinically proven to be effective with a known

tolerability profile.

IIII

Improvement typically seen within 4–8 weeks.⁴